Who
Lisa Ricciardi
CEO & President
Company insider
Files Form 4 as: CEO & President, Cognition Therapeutics; Director, Contrafect; Director, Chimerix; Director, Sepracor Inc /de/.
In numbers
- Trades disclosed
- 50
- Buys
- 8
- Sells
- 0
- Bought
- $360K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 12 Nov 2007
- Last trade
- 16 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Apr 2026filed 20 Apr 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K9,175 at $1.10 | filing |
| 16 Apr 2026filed 20 Apr 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $10K9,175 at $1.10 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $6,5525,850 at $1.12 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $6,5525,850 at $1.12 | filing |
| 4 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $53K51,704 at $1.03 | filing |
| 4 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $53K51,704 at $1.03 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $29K26,036 at $1.12 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $29K26,036 at $1.12 | filing |
| 18 Dec 2025filed 22 Dec 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 18 Dec 2025filed 22 Dec 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $35K23,400 at $1.50 | filing |
| 29 Jul 2025filed 31 Jul 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K23,400 at $0.67 | filing |
| 15 Feb 2025filed 18 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $3,9056,619 at $0.59 | filing |
| 4 Feb 2025filed 4 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code A | —631,300 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Code F | $19K28,960 at $0.67 | filing |
| 31 Jan 2025filed 4 Feb 2025 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $30K38,851 at $0.77 | filing |
| 14 Mar 2024filed 14 Mar 2024 | CGTX Cognition TherapeuticsBiotechnology | SEC FORM 4 Bought | $9,9755,700 at $1.75 | filing |
| 15 Feb 2024filed 20 Feb 2024 | CGTX Cognition Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
Cognition Therapeutics (NASDAQ:CGTX) Stock Falls 2% – Here's WhyCGTX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Lisa Ricciardi; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.